HeyJaredDonnelly McDowell
- Indexed articles, last 90 days
- 7
- Latest publication
- Sep 17, 2026
- Outlet visibility, for Mondaq
- Top 500K sites
- Earliest in this view
- Jul 23, 2026
Latest articles
FTC Releases FAQs On Auto Pricing: What Dealers And Advertisers Need To Know (opens the original)
Read excerpt
If you’re a dealer, an ad agency handling automotive accounts, or in-house counsel advising automotive clients, the Commission’s latest guidance on auto pricing transparency deserves a careful read. The guidance echoes familiar principles we’ve heard in other areas from federal and state regulators related to the expectation for all-in pricing, with important nuances unique to the auto industry. The enforcement backdrop is significant. Already in 2026, the FTC has filed two enforcement actions a
FDA’s Proposed GRAS Rule - Mandatory Notifications, Expanded Scope, And Open Questions (Podcast) (opens the original)
Read excerpt
What could a major change to the GRAS framework mean for food companies? In this episode, we unpack the FDA’s proposed rule that would transform the long-standing voluntary GRAS notification system into a mandatory one, while also expanding the scope of the program and creating a streamlined pathway for certain substances already on the market. We explore what the proposal could mean for companies relying on self-affirmed GRAS determinations, including new notification requirements, transition p
“Junk Fees” Summer 2026 Roundup Part 1 – Illinois, NYC, And DC (Podcast) (opens the original)
Read excerpt
Kelley Drye Ad Law Access Podcast · “Junk Fees” Summer 2026 Roundup Part 1 – Illinois, NYC, and DC Are “junk fees” about to get even harder to hide? In this episode, we unpack the first installment of Kelley Drye’s Summer 2026 roundup on fee transparency, covering new and proposed developments in Illinois, New York City, and Washington, DC. From Illinois’ new law requiring advertised prices to include mandatory fees, to New York City’s proposed industry-neutral rules targeting surprise charges,
FDA Advisory Committee Recommends Several Peptides For Compounding For Various Uses Despite Staff Opposition- What Stakeholders Need To Know (Podcast) (opens the original)
Read excerpt
What happens when an FDA advisory committee recommends opening the door to peptide compounding, but FDA staff strongly disagree? In this episode, we unpack the FDA Pharmacy Compounding Advisory Committee’s recommendation to add six of seven peptides under review to the 503A Bulks List for uses ranging from obesity and wound healing to insomnia, despite agency staff raising concerns about insufficient safety and effectiveness data, limited clinical evidence, and potential safety risks. We also ex
FDA’s Proposed GRAS Rule: Mandatory Notifications, Expanded Scope, And Open Questions (opens the original)
Read excerpt
Following through with long-stated intentions, FDA yesterday published a proposed rule that could fundamentally reshape how food substances reach the U.S. market under the Generally Recognized as Safe (GRAS) framework. Under the proposed rule, what has historically been a voluntary notification system would become mandatory, requiring companies to disclose their GRAS conclusions to FDA before—or shortly after—introducing substances into interstate commerce. The rule would also establish a stream
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For Mondaq, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.